A Phase II trial evaluating ESK981, a multi-tyrosine kinase inhibitor, combined with nivolumab in metastatic castration-resistant prostate cancer (mCRPC) was terminated due to futility.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.